期刊文献+

不同剂量国产甲磺酸左氧氟沙星在健康志愿者体内药动学研究 被引量:1

Pharmacokintics of domestic levofloxacin mesylate in healthy volunteers after oral administration of various dose
暂未订购
导出
摘要 目的 研究健康志愿者单次 po不同剂量国产甲磺酸左氧氟沙星的药动学。 方法  30名健康志愿者分 3组 po 10 0 ,2 0 0 ,30 0mg甲磺酸左氧氟沙星 ,血及尿药浓度均采用HPLC测定。数据用 3P87药动学程序进行模型拟合并计算药动学参数。结果 甲磺酸左氧氟沙星药 时曲线符合二室模型 ,po 10 0 ,2 0 0 ,30 0mg后其主要药动学参数 :tpeak分别为 1.2 87,1.12 1,1.386h ,t1/2 β分别为 7.6 6 9,6 .5 6 9,6 .187h ,AUC分别为 11.418,2 1.5 0 2 ,32 .746mg·h·L-1,0~ 2 4h尿药回收率分别为72 .2 4% ,6 6 .31% ,6 8.6 2 %。主要药动学参数在 3个剂量组之间无显著性差异。结论 国产甲磺酸左氧氟沙星在健康人体内的处置无剂量依赖性。 OBJECTIVE To study pharmacokintics of domestic levofloxacin mesylate in healthy volunteers after oral administration of various dose.METHODS Thirty healthy volunteers were divided into 3 grops and given single oral dose of levofloxacin mesylate 100,200,300 mg.The levofloxacin concentrations in serum and urine were determined by HPLC methods.The 3P87(pharmacokinetics program) was used for analysis of metabolism process and parameters of kinetics.RESULTS It ws found that the serum concentrations time curves were fitted to a two compartment model.The main pharmacokinetic parameters were as following: t peak (1.287±0.385) h,(1.121±0.316) h,(1.386±0.233) h; t 1/2 β(7.669±1.697) h,(6.596±1.207) h,(6.187±0.972) h;and AUC ( 11.418 ±1.834) mg·h·L -1 ,(21.502±4.805) mg·h·L -1 ,and (32.764±3.564) mg·h·L -1 ,respectively.There was no significant difference of main pharmacokinetic parameters among three dose groups.CONCLUSION The disposition of levofloxacin mesylate in healthy volunteers was dose independent.This study will provide a scientific basis for the clinical applications.
机构地区 卫生部北京医院
出处 《中国药学杂志》 CAS CSCD 北大核心 2000年第6期394-396,共3页 Chinese Pharmaceutical Journal
关键词 甲磺酸左氧氟沙星 高效液相色谱法 血药浓度 levofloxacin mesylate HPLC concentration pharmacokinetics
  • 相关文献

参考文献2

共引文献104

同被引文献35

  • 1张菁,郁继诚,施耀国,周乐,叶信予,朱德妹,张婴元.左氧氟沙星药代动力学/药效学研究[J].中华医学杂志,2005,85(27):1926-1932. 被引量:61
  • 2桑福德.热病:桑福德抗微生物治疗指南[M].范洪伟,吕玮,吴东,等,译.新译41版.北京:中国协和医科大学出版社,2011:58、61.
  • 3中华人民共和国卫生部医政司,卫生部合理用药专家委员会.国家抗微生物治疗指南[M].北京:人民卫生出版社,2012:49-53.
  • 4刘克辛,韩国柱.临床药物代谢动力学[M].2版.北京:科学出版社,2010:189-345.
  • 5Sherwin CM, Kiang TK, Spigarelli MG, etal. Fundamentals of population pharmacokinetic modelling: validation methods [J]. Clin Pharrnacokinet, 2012, 51 (9) : 573-590.
  • 6Sheiner LB, Rosenberg B, Marathe VV. Estimation of popu- lation characteristics of pharmacokinetie parameters from rou- tine clinical dataEJ2. J Pharmacokinet Biopharm, 1977, 5(5): 445-479.
  • 7Joerger M. Covariate pbarmacokinetie model building in oneol-ogy and its potential clinical relevance[J]. AAPS J, 2012, 14 (1): 119 132.
  • 8Andersson MI, Macowan AP. Development of the quinolones [J]. J Antimicrob Chemother, 2003, 51(Suppl 1): S1-Sll.
  • 9Destache CJ, Pakiz CB, Larsen C, et al. Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experi- mental rabbit meningitis model[J]. J Antimicrob Chemother, 2001, 47(5): 611-615.
  • 10Pranger AD, Alffenaar JW, Wessels AM, et al. Determina tion of moxifloxaein in human plasma, plasma ultrafihrate, and cerebrospinal fluid by a rapid and simple liquid chromatog- raphy- tandem mass spectrometry method[J]. J Anal Toxieol, 2010, 34(3): 135-141.

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部